Meeting
2020 Gastrointestinal Cancers Symposium
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Authors
Ahmed Omar Kaseb
The University of Texas MD Anderson Cancer Center, Houston, TX
Ahmed Omar Kaseb , Dan G. Duda , Hop Sanderson Tran Cao , Yehia I. Abugabal , Luis M. Vence , Asif Rashid , Roberto Pestana , Jorge M. Blando , Shalini Singh , Jean-Nicolas Vauthey , Manal Hassan , Hesham M. Amin , Aliya Qayyum , Yun Shin Chun , Ching-Wei David Tzeng , Divya Sakamuri , Robert A. Wolff , James C. Yao , James Patrick Allison , Padmanee Sharma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT03510871
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 486)
Abstract #
486
Poster Bd #
A11
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Omar Kaseb
Poster
2020 ASCO Virtual Scientific Program
Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Omar Kaseb
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
First Author: Yara L. Verschoor